Hikma Pharmaceuticals Shareholders Approve Dividend and Buybacks

Hikma Pharmaceuticals (GB:HIK) has released an update.

Hikma Pharmaceuticals PLC’s Annual General Meeting concluded with all proposed resolutions passed, including the approval of a final dividend of 47 cents per share scheduled for payment on May 3, 2024. Shareholders showed strong support across various resolutions, with a notable approval for the company to purchase ordinary shares, enhancing shareholder value through potential buyback programs. The detailed voting results will be accessible via the FCA’s National Storage Mechanism.

For further insights into GB:HIK stock, check out TipRanks’ Stock Analysis page.